SCHEMBL3987476

SCHEMBL3987476

O=C(O)c1c(NS(=O)(=O)c2ccc(F)c(F)c2)ccc2ccccc12

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 4/20 0.76
METAP1 P53582 1/20 0.72
CHEK1 O14757 1/20 0.52
CDK8 P49336 1/20 0.52
NEK2 P51955 1/20 0.52
LIMK1 P53667 1/20 0.52
KMT2A Q03164 3/20 0.51
ALDH1A1 P00352 2/20 0.49
HSD17B10 Q99714 1/20 0.49
GLO1 Q04760 1/20 0.49
MEN1 O00255 2/20 0.45
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45
RECQL P46063 1/20 0.45
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
ATM Q13315 1/20 0.44
WDR5 P61964 1/20 0.44
MCL1 Q07820 1/20 0.44
FABP4 P15090 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3982715 0.88 METAP2 (0.65) METAP2METAP1CHEK1CDK8NEK2
SCHEMBL3982656 0.86 METAP2 (1.00) METAP2METAP1CHEK1CDK8NEK2
SCHEMBL3981272 0.85 METAP2 (0.76) METAP2METAP1CHEK1CDK8NEK2
SCHEMBL3986500 0.84 METAP2 (1.00) METAP2METAP1CHEK1CDK8NEK2
SCHEMBL3985677 0.84 METAP2 (0.82) METAP2METAP1CHEK1CDK8NEK2
SCHEMBL3985482 0.81 METAP2 (0.69) METAP2METAP1CHEK1CDK8NEK2
SCHEMBL3984291 0.81 METAP2 (0.82) METAP2METAP1CHEK1CDK8NEK2
SCHEMBL3987782 0.81 METAP2 (0.82) METAP2METAP1CHEK1CDK8NEK2
SCHEMBL3984005 0.81 METAP2 (0.76) METAP2METAP1KMT2AALDH1A1MEN1
SCHEMBL3980582 0.80 METAP2 (0.64) METAP2METAP1KMT2AMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-04-08 US claimed
US-7491718-B2 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES (US) 2009-02-17 US disclosed
EP-1549613-A1 SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY Abbott Laboratories (US) 2005-07-06 EP disclosed
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity ABBVIE INC. 2004-08-26 US disclosed
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-08-12 US disclosed
WO-2004033419-A1 SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY ABBOTT LABORATORIES (US) 2004-04-22 WO disclosed
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885METAP1 2/4885CHEK1 4142/4885
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885METAP1 2/4885CHEK1 4142/4885
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885METAP1 2/4885CHEK1 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.